TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06124170

Intervention type: PROCEDURE
Intervention: Preoperative pain managment
Description: propaganda and education on pain; Preemptive analgesia with celecoxib (200 mg bid) 2 days before surgery

Intervention type: PROCEDURE
Intervention: Intraoperative pain managment
Description: Squeeze to expel blood (tourniquet); Before skin suture, 20 mL 0.5% ropivacaine was given subcutaneously for local infiltration anesthesia;

Intervention type: PROCEDURE
Intervention: Intraoperative pain managment
Description: Squeeze to expel blood (tourniquet); Before skin suture, 20 mL 0.5% ropivacaine was given subcutaneously for local infiltration anesthesia;

Intervention type: PROCEDURE
Intervention: Intraoperative pain managment
Description: Squeeze to expel blood (tourniquet); Before skin suture, 20 mL 0.5% ropivacaine was given subcutaneously for local infiltration anesthesia;

Intervention type: PROCEDURE
Intervention: Postoperative pain managment
Description: The intravenous analgesia pump was placed until 48 h after surgery;On the second day after surgery, celecoxib (200 mg bid) was administered orally, and buprenorphine transdermal patch was applied externally until hospital discharge;FNB catheter was placed under the guidance of ultrasound and connected with an analgesic pump, the anesthesia lasted until 48 h after surgery ‡

Intervention type: PROCEDURE
Intervention: Postoperative pain managment
Description: The intravenous analgesia pump was placed until 48 h after surgery;On the second day after surgery, celecoxib (200 mg bid) was administered orally, and buprenorphine transdermal patch was applied externally until hospital discharge;FNB catheter was placed under the guidance of ultrasound and connected with an analgesic pump, the anesthesia lasted until 48 h after surgery ‡

Intervention type: PROCEDURE
Intervention: Postoperative pain managment
Description: The intravenous analgesia pump was placed until 48 h after surgery;On the second day after surgery, celecoxib (200 mg bid) was administered orally, and buprenorphine transdermal patch was applied externally until hospital discharge;FNB catheter was placed under the guidance of ultrasound and connected with an analgesic pump, the anesthesia lasted until 48 h after surgery ‡
Study: NCT01584596

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Dietary Guidelines
Description: This group will receive dietary counseling to reduce their overall dietary food intake by 100 kcal/day, as prescribed by the dietary guidelines for the prevention of weight gain, and to follow an adapted eating pattern (to be determined from formative research in Phase I research).~The education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. During the adoption phase, participants will meet for one session per week for the first four weeks. During this session their interim weight will be recorded before they receive their session. During the adherence phase, participants will be contacted by telephone biweekly by a trained interventionist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Dietary Guidelines
Description: This group will receive dietary counseling to reduce their overall dietary food intake by 100 kcal/day, as prescribed by the dietary guidelines for the prevention of weight gain, and to follow an adapted eating pattern (to be determined from formative research in Phase I research).~The education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. During the adoption phase, participants will meet for one session per week for the first four weeks. During this session their interim weight will be recorded before they receive their session. During the adherence phase, participants will be contacted by telephone biweekly by a trained interventionist.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Physical Activity Guidelines
Description: The physical activity education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. The adoption phase will be for 1 hour and 45 minutes for the first 4 weeks with classes occurring once per week in conjunction with the DG education classes. During the adoption phase, participants monitor their own walking using pedometers and attend weekly group meetings to review the previous week's walking behaviors, discuss preferred strategies for success, and set personally relevant and incremental steps/day goals. During the adherence phase (the remaining 8 weeks), participants will continue with their self-monitoring and goal-setting (using their pedometers), with reduced contact with the study interventionists over the telephone (biweekly).
Study: NCT03153176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: Training program 30 hours accumulated before, during and after intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual level
Description: 7 to 10 minutes in Physical Education in class time, 3 sections for week during lunch break

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Organizational level
Description: Inclusion of actions in the school curriculum: counseling sections with health for parents and adolescent, active lesson breaks during theoretical class, gardening experience in school, nutrition guidance for school lunch professionals.
Study: NCT04609735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electric Dry Needling, Manual Therapy, Exercise and Ultrasound
Description: Electric Dry Needling, Manual Therapy, Exercise and Ultrasound

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy, Exercise and Ultrasound
Description: Electric Dry Needling, Manual Therapy, Exercise and Ultrasound vs. Manual Therapy, Exercise and Ultrasound
Study: NCT03102632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Water Intake
Description: After 6 months of usual, unchanged diet and fluid intake, participants will be asked to increase the daily fluid intake based on the principal investigator's prescription. The actual amount of extra water prescribed will depend on the results of the participant's 24 hour urine test.
Study: NCT01232101

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: covered or uncovered stents
Description: Patients are randomized to covered or uncovered stent. Stent patency is monitored and compared as well as complications, efficacy and technical success.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: covered or uncovered stents
Description: Patients are randomized to covered or uncovered stent. Stent patency is monitored and compared as well as complications, efficacy and technical success.
Study: NCT01860300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Potassium Clavulanate Combination
Description: Amoxicillin-Potassium Clavulanate Combination will be prescribed at the dose of 25/3.6 mg/kg/day for 10 days, 2 times/day, as oral suspension.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01827982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 1mg
Description: JNJ-54861911 1 mg will be administered as a single oral dose after an overnight fast of at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 3 mg
Description: JNJ-54861911 3 mg will be administered as a single oral dose.
Study: NCT03968588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus(reduced), Mycophenolate mofetil(standard)
Description: tacrolimus target trough blood level: 3\~8ng/mL MMF dose: 1.5\~2g/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus(standard), Mycophenolate mofetil(reduced)
Description: tacrolimus target trough blood level: 5\~15ng/mL MMF dose: 0.5\~1g/d
Study: NCT01827982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 9 mg
Description: JNJ-54861911 9 mg will be administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 27 mg
Description: JNJ-54861911 27 mg will be administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 81 mg
Description: JNJ-54861911 81 mg will be administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 160 mg
Description: JNJ-54861911 160 mg will be administered as a single oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 tbd
Description: The dose of JNJ-54861911 will be derived from the results obtained in Parts 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-54861911 9 mg
Description: Study drug will be administered after an overnight fast of at least 10 hours and within 120 minutes after placement of the spinal catheter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be given as a single oral dose.
Study: NCT01612650

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2D mammography
Description: 2 incidences 2D analogic mammography

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2D mammography
Description: 2 incidences 2D analogic mammography
Study: NCT00927849

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lateral internal sphincterotomy (LIS)
Description: closed lateral internal sphincterotomy was done under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.
Study: NCT01612650

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2D mammography
Description: 2 incidences 2D analogic mammography
Study: NCT00927849

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerin trinitrate (GTN)
Description: All were instructed to apply the GTN ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin injection (BTX A)
Description: All were injected with botulinum toxin injection (BTX- A) in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.
Study: NCT03536845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D 3
Description: oral drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D 3
Description: oral drops
Study: NCT01148615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (XRP6976)
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT03074786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine
Description: Silicone elastomer vaginal matrix ring

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Tablets to be taken orally daily
Study: NCT05139888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single wavelength light (red) only
Description: Clinicians should confirm a diagnosis of distal subungual onychomycosis (DSO). Clinician should assign an OSI score to each nail using the Onychomycosis Severity Index (OSI). The ToeFX system is intended for use in any room in which standard foot care treatments are routinely administered. Debridement should not be carried out more proximally than the most proximal margin of the dystrophic nail, as this can interfere with assessment of clear nail area attributable to the device intervention. The clinician should debride the nail, apply formula, and position the affected foot directly under the ToeFX ClearToe Therapy red light (640-660 nm). For safety, the light has a built-in timer and automatically switches off after 15 minutes. The process should be repeated every 2 weeks for 6 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dual wavelength light (red/blue)
Description: Clinicians should confirm a diagnosis of distal subungual onychomycosis (DSO). Clinician should assign an OSI score to each nail using the Onychomycosis Severity Index (OSI). The ToeFX system is intended for use in any room in which standard foot care treatments are routinely administered. Debridement should not be carried out more proximally than the most proximal margin of the dystrophic nail, as this can interfere with assessment of clear nail area attributable to the device intervention. The clinician should debride the nail, apply formula, and position the affected foot directly under the ToeFX ClearToe Therapy dual wavelength light (640-660 nm and 405-450 nm). For safety, the light has a built-in timer and automatically switches off after 15 minutes. The process should be repeated every 2 weeks for 6 months..
Study: NCT01722201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone Tablet 1 mg
Description: 1 mg tablet once a day
Study: NCT02961192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive social incentive
Description: A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Competitive social incentive
Description: Participants in this intervention will be competing against each other in the game.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative social incentive
Description: Participants in this intervention will be working with each other in the game.
Study: NCT01688739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered by subcutaneous injection or intravenous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection or intravenous injection
Study: NCT00996801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5442
Description: MK-5442 tablets (randomized to a dose of 5, 7.5, 10 or 15 mg) taken orally, once-daily, for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5442
Description: MK-5442 tablets (randomized to a dose of 5, 7.5, 10 or 15 mg) taken orally, once-daily, for 12 months
Study: NCT01321333

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HuCNS-SC cells
Description: single dose intramedullary transplantation of HuCNS-SC cells in the thoracic spinal cord
Study: NCT01070628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stalevo (levodopa/ carbidopa/ entacapone)
Description: 150mg, 125 mg, 100mg, 75mg of levodopa q.i.d. in 3.5 h interval

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sinemet (levodopa/carbidopa)
Description: 150 or 100 mg levodopa q.i.d. in 3.5 hr interval
Study: NCT00996801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5442
Description: MK-5442 tablets (randomized to a dose of 5, 7.5, 10 or 15 mg) taken orally, once-daily, for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-5442
Description: MK-5442 tablets (randomized to a dose of 5, 7.5, 10 or 15 mg) taken orally, once-daily, for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to MK-5442
Description: Matching placebo to MK-5442 taken orally, once-daily, for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MK-5442
Description: Matching placebo to MK-5442 taken orally, once-daily, for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alendronate Sodium
Description: Alendronate tablets 70 mg, taken orally, once-weekly, for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months
Study: NCT01149161

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routine central neck dissection
Description: Level VI neck node dissection during thyroid operation
Study: NCT01050140

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high sugar diet
Description: 25% of dietary energy from fructose or glucose

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: high sugar diet
Description: 25% of dietary energy from fructose or glucose
Study: NCT04102657

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: Participants will be instructed to limit their daily food consumption to an 8-hour period in the day of their choosing. For the 16-hour fasting period, subjects are to eliminate caloric intake.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting
Description: Participants will be instructed to limit their daily food consumption to an 8-hour period in the day of their choosing. For the 16-hour fasting period, subjects are to eliminate caloric intake.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free-Living Diet
Description: Participants will maintain their current daily food consumption with no caloric restriction. Patient must not have participated in a specialized diet or weight loss program within 2 weeks of enrollment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Free-Living Diet
Description: Participants will maintain their current daily food consumption with no caloric restriction. Patient must not have participated in a specialized diet or weight loss program within 2 weeks of enrollment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Left Arm Exercise
Description: Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the left arm. In the middle of the study, participants will switch to the right arm to complete their unilateral arm exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Left Arm Exercise
Description: Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the left arm. In the middle of the study, participants will switch to the right arm to complete their unilateral arm exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Right Arm Exercise
Description: Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the right arm. In the middle of the study, participants will switch to the left arm to complete their unilateral arm exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Right Arm Exercise
Description: Participants will complete a 20-minute period of rest followed by a 20-minute unilateral arm exercise on the right arm. In the middle of the study, participants will switch to the left arm to complete their unilateral arm exercises.
Study: NCT03480841

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Language ENhancement Assessment/intervention system
Description: The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. Researchers will provide an initial feedback session to mothers, which will include reviewing the LENA visual output from the previous recording and how mothers can access the output on their own for future recordings. Mothers will independently use the LENA system and access the output on their own.
Study: NCT00996801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate
Description: Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months
Study: NCT01722201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: 1 mg tablet once a day
Study: NCT00946517

Intervention type: OTHER
Intervention: Questionnaires
Description: Parenting and behavioral questionnaires

Intervention type: OTHER
Intervention: Questionnaires
Description: Parenting and behavioral questionnaires
Study: NCT00996801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Description: Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium carbonate
Description: Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Alendronate
Description: Placebo to alendronate once-weekly for 12 months
Study: NCT04755972

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inhalation of N-acetylcysteine
Description: Group 1 will receive N-acetylcysteine inhalation every 12 hours from the beginning of invasive mechanical ventilation.
Study: NCT00996801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Alendronate
Description: Placebo to alendronate once-weekly for 12 months
Study: NCT03531307

Intervention type: OTHER
Intervention: Data correlation
Description: Correlation between lactate levels and Ki-67 index